NAD+ + NMN Therapy (Infusion)
NAD+ + NMN Therapy (Infusion)
NAD+ + NMN Therapy (Infusion)
Other
Free & no obligation · Replies in minutes
NAD+ infusion therapy replenishes declining NAD+ levels in the body to support cellular repair, energy metabolism, and anti-aging benefits, often combined with NMN-based support
How it works
Simple, guided, and free to start.
- 1
Ask free on WhatsApp
Tell us what you need — no cost, no obligation.
- 2
We confirm the details
Our team checks price, availability, and what's included directly with the hospital.
- 3
We plan your trip
Scheduling, an interpreter if you need one, and the logistics — all handled.
- 4
Care & follow-up
You get your treatment, and we stay with you afterward.
Why book with Medifly
Package Included
- NAD+ intravenous infusion (100mg or 200mg dosage options)
Benefits
- Supports cellular energy production
- promotes anti-aging at cellular level
- enhances DNA repair
- improves overall vitality
Frequently Asked Question
Free & no obligation · Replies in minutes

Tokyo Relife Clinic
More packages at Tokyo Relife Clinic
Blood Test & Lab
Immune Function Test
This immune function test assesses the body’s immune system status, helping evaluate immune strength, detect imbalances, and support prev…
- Comprehensive immune function assessment through specialized testing
Fertility & Reproductive Health
Ovarian Function Test
This ovarian function test evaluates reproductive health by assessing ovarian activity and hormonal balance, helping to understand fertil…
- Blood test to evaluate ovarian function and related hormonal indicators

Cancer Screening
Tumor Marker Panel ※Female (50min)
This tumor marker panel for females measures biomarkers such as AFP, CEA, CA19-9, CA-125, CA-15-3, and PIVKA-II to support early detectio…
- Blood test including AFP
- CEA
- CA19-9

Cancer Screening
Tumor Marker Panel ※Male (45min)
This tumor marker panel for men measures key biomarkers including AFP, CEA, CA19-9, PSA, and PIVKA-II to support early detection and risk…
- Blood test including AFP
- CEA
- CA19-9